SCHEMBL4677401

SCHEMBL4677401

CC(=O)c1ccc(Cc2cc(C(=O)C=C(O)C(=O)O)c[nH]2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.45
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.35
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
SMYD3 Q9H7B4 1/20 0.33
PYCR1 P32322 1/20 0.33
TSHR P16473 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
TBXAS1 P24557 2/20 0.32
RXRA P19793 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAOB P27338 1/20 0.31
AKR1C3 P42330 1/20 0.31
MAPT P10636 1/20 0.31
RXRB P28702 1/20 0.31
RXRG P48443 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677395 1.00 KMT2A (0.45) KMT2ALMNAHSD17B10PPARGPPARA
SCHEMBL4672398 0.88 SRD5A2 (0.39) KMT2ALMNASMN1; SMN2ALDH1A1HTT
SCHEMBL4672402 0.88 SRD5A2 (0.39) KMT2ALMNASMN1; SMN2ALDH1A1HTT
SCHEMBL4671116 0.87 HCAR2 (0.39) KMT2ALMNAHRH3SMN1; SMN2ALDH1A1
SCHEMBL4671120 0.87 HCAR2 (0.39) KMT2ALMNAHRH3SMN1; SMN2ALDH1A1
SCHEMBL4679210 0.86 HRH3 (0.36) TSHRHRH3ALDH1A1
SCHEMBL4675004 0.86 ALDH1A1 (0.38) KMT2ALMNASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL4679215 0.86 HRH3 (0.36) TSHRHRH3ALDH1A1
SCHEMBL4675001 0.86 ALDH1A1 (0.38) KMT2ALMNASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL4672130 0.85 KDM5A (0.41) KMT2ALMNAPPARGPPARASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885LMNA 659/4885HSD17B10 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.